Serial No.: 09/784,618

Page 3

Marked Up Version of Amendments

IN THE SPECIFICATION

On page 5, in the second line of the third full paragraph, after "colonic" insert --carcinomas,-- so the third full paragraph on page 5 reads as follows:

The compounds of formula (I) are suitable for treating various cancerous diseases, such as testicular tumors, ovarian carcinomas, bladder carcinomas, colonic <u>carcinomas</u>, prostatic carcinomas, parvocellular and non-parvocellular bronchial carcinomas, carcinomas of the cephalic and cervical parts, carcinomas of the thoracic and abdominal regions, cervical and endometrial carcinomas, sarcomas and melanomas as well as leukemias. The treatment of the parvocellular bronchial carcinoma or colorectal carcinoma is preferred. The treatment can also be carried out as a treatment associated with a radiotherapy or before and/or after an operation.

IN THE CLAIMS

- 12. (New) The pharmaceutical preparation according to claim 6, wherein the further cytostatic agent is cisplatin, methotrexate, aminopterin, dcarbacine, nitroso urea compounds, fluorouracil, bleomycin, daunomycin, daunorubicin, doxorubicin, mithramycin, or mitomycin C.
- 13. (New) The use according to claim 10, wherein said cancerous disease is selected from testicular tumors, ovarian carcinomas, bladder carcinomas, colonic carcinomas, prostatic carcinomas, parvocellular and non-parvocellular bronchial carcinomas, carcinomas of the cephalic and cervical parts, carcinomas of the thoracic and abdominal regions, cervidal and endometrial carcinomas, sarcomas, melanomas and leukemias.